| 0.7675 -0.012 (-1.59%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.14 | 1-year : | 1.3 |
| Resists | First : | 0.98 | Second : | 1.12 |
| Pivot price | 0.84  |
|||
| Supports | First : | 0.75 | Second : | 0.63 |
| MAs | MA(5) : | 0.79 |
MA(20) : | 0.87 |
| MA(100) : | 0.85  |
MA(250) : | 0.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.1 |
D(3) : | 10.3 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 1.45 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMUX ] has closed above bottom band by 11.2%. Bollinger Bands are 14.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.8 | 0.8 - 0.8 |
| Low: | 0.75 - 0.75 | 0.75 - 0.76 |
| Close: | 0.76 - 0.77 | 0.77 - 0.77 |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Fri, 17 Oct 2025
We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate - Sahm
Wed, 01 Oct 2025
Breakthrough Celiac Disease Treatment: Immunic's IMU-856 Shows Positive Effects in Phase 1 Trial Presentation - Stock Titan
Wed, 01 Oct 2025
Immunic to Participate in Scientific and Investor Conferences in October - PR Newswire
Mon, 29 Sep 2025
Chardan Capital Initiates Coverage on Immunic (IMUX) with a 'Buy' Rating | IMUX Stock News - GuruFocus
Thu, 04 Sep 2025
Immunic to Participate in Investor and Scientific Conferences in September - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 53.5 (%) |
| Shares Short | 10,430 (K) |
| Shares Short P.Month | 9,830 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89 % |
| Return on Equity (ttm) | -209 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -90 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 2.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|